All In Biotech

Drug Trial Radar · NCT02883543

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Phase III Study of Icotinib With Concurrent Radiotherapy as First-line Treatment for Unresectable/Oligometastasis NSCLC With EGFR Activating Mutation: a Prospective, Multicentre, Open-label, Randomised Study

Last checked: Nov 19, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

330

Planned (sponsor's estimate)

Start

Jun 2016

Primary completion

Jun 2018

Study completion Jun 2019

Sponsor

Sponsor type
Academic, hospital or other
First posted
Aug 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • icotinibDrug

    Icotinib is orally administered three times per day.

  • ChemotherapyDrug

    Chemotherapy is given by intravenous administration. Three regimens are available in this study. Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2. Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2. Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2

  • RadiotherapyRadiation

    5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: 2 years
  2. Incidence of radiation injure of the lungsTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.